Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Description of Business, Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)

Description of Business, Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)				1 Months Ended	3 Months Ended
	Jun. 11, 2018	Jun. 01, 2017 USD ($)	Feb. 01, 2012 USD ($)	Dec. 31, 2005 USD ($)	Feb. 28, 2021 USD ($) Segment Unit	Nov. 30, 2020 USD ($)	Feb. 29, 2020 USD ($)	Feb. 23, 2021
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Number of reportable segments \| Segment					3
Deferred revenue					$ 36,831,740
Warranty payment		$ 100,000	$ 75,000	$ 50,000
Commission paid					13,507		$ 11,535
Additional capitalized contract acquisition costs, net of amortization expense					18,262		23,320
Impairment of contract assets					0		0
Impairment of public inventory						$ 1,284,238
Uncertain tax provisions					0
Provisions for interest or penalties related to uncertain tax positions					0		0
Impairment on long lived assets					0		0
Stock-based option compensation expense					85,000		224,000
Unrealized holding (losses) gains, marketable securities					$ (3,000)		$ 55,000
Number of units anticipated to be sold each year \| Unit					18
Percentage of decline in annual sales					3.00%
Payment warranty				$ 50,000
Increased payment warranty		$ 100,000	$ 75,000
Discount Rate [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contingent consideration measurement input					5.50
ASU 2016-02 [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]					true
Change in Accounting Principle, Accounting Standards Update, Adoption Date					Dec. 01, 2019
Change In Accounting Principle Accounting Standards Update Transition Option Elected [Extensible List]					us-gaap:AccountingStandardsUpdate201602RetrospectiveMember
Cord:Use [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Acquisition date	Jun. 11, 2018
Duke University [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period								15 years
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] \| Duke University [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Agreement expiration date					Jan. 31, 2025
Inventory, in units \| Unit					6,000
Number of units, per month \| Unit					12
Maximum [Member] \| Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] \| Duke University [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Inventory, in units \| Unit					144
Accounts Receivables [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Period of doubtful for accounts receivable due from client					30 days
Option One [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					21 years
Option Two [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					1 year
Option Three [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					lifetime
Contracted storage amortization description					The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue.